Menu
Not yet recruiting NCT07711548

Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?

No phase Interventional Obesity & Overweight Weight Loss Maintenance

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: NutriAct plus, Rescue VLCD.
Who it may be relevant to
Registry conditions: Obesity & Overweight, Weight Loss Maintenance. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

DIETary Strategies to stabiLize Incretin-based Weight Loss in Obesity Management

Overview

So far, treatment with semaglutide (Wegovy) for therapy of obesity demonstrates substantial effects. However, most patients do not desire life-long pharmaceutical therapy or discontinue this treatment regime. This is accompanied by rapid weight regain. Moreover, numerous patients are open to an intermittent therapy. This trial aims to investigate whether two diet interventions can keep weight stable after weight loss with semaglutide in people with obesity or overweight.

Interventions

  • Behavioral NutriAct plus
    Dietary pattern, vegetarian version of the NutriAct pattern
  • Behavioral Rescue VLCD
    Very low calorie diet as full meal replacement over 28 days in case of weight regain

Primary outcome measures

  • weight in kg [Time frame: body weight in kg after weight loss (3 to 5 months) and dietary intervention (12 months)]

Eligibility criteria

Inclusion criteria

  • BMI ≥ 30 kg/m² OR ≥ 27 kg/m² with concomitant cardiometabolic risk factors (metabolic syndrome, elevated blood pressure, dyslipidemia or impaired glucose metabolism (but not type 2 diabetes)

Exclusion criteria

  • BMI ≥ 45 kg/m²
  • intake of glucose lowering drugs
  • presence of incretin-based treatment
  • acute severe CVD
  • uncontrolled hypertension
  • severe hepatic or renal diseases
  • severe food allergy or malabsorption disease
  • active cancer
  • condition after bariatric surgery
  • history of eating disorder
  • concurrent pregnancy and breastfeeding

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07711548 · U1111-1326-4843

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗